Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.
Analysts anticipate Twist Bioscience to report an earnings per share (EPS) of $-0.46. Anticipation surrounds Twist Bioscience ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback